Journal of Histochemistry and Cytochemistry Priciples for Free Access to Science
  Search:   
    >> Advanced Search

Guidelines | Subscriptions | About | exPRESS - Current - Archive | Business Information | Contact
Originally published as JHC exPRESS on May 17, 2007.
doi:10.1369/jhc.7A7235.2007
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jhc.7A7235.2007v1
55/9/955    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tsai, W.-C.
Right arrow Articles by Chao, Y.-C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tsai, W.-C.
Right arrow Articles by Chao, Y.-C.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Journal of Histochemistry and Cytochemistry
Volume 55 (9): 955-962, 2007
Copyright ©The Histochemical Society, Inc.

Association of Cortactin and Fascin-1 Expression in Gastric Adenocarcinoma: Correlation With Clinicopathological Parameters

Wen-Chiuan Tsai, Jong-Shiaw Jin, Wei-Kuo Chang, De-Chuan Chan, Ming-Kung Yeh, Shiou-Chih Cherng, Li-Fan Lin, Lai-Fa Sheu and You-Chen Chao

Department of Pathology (W-CT,J-SJ,L-FS), Division of Hepatogastroenterology, Department of Internal Medicine (W-KC,Y-CC), Division of General Surgery, Department of Surgery (D-CC), Department of Clinical Pharmacology (M-KY), and Department of Nuclear Medicine (S-CC,L-FL), Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan

Correspondence to: You-Chen Chao, MD, Division of Hepatogastroenterology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, No. 325, Sec. 2, Cheng-Kung Road, Neihu 114, Taipei, Taiwan. E-mail: ab95057{at}hotmail.com


   Summary
Top
 Summary
Introduction
 Materials and Methods
 Results
 Discussion
 Literature Cited
 
Cortactin and fascin-1 are important factors in tumor progression. We tested the hypothesis that cortactin and fascin-1 expression correlates with clinicopathological parameters of gastric adenocarcinoma. Immunohistochemical analysis of cortactin and fascin-1 was done using tissue microarrays of 100 surgical specimens, including 20 well-differentiated, 20 moderately differentiated, and 60 poorly differentiated gastric adenocarcinomas. Among the 20 well-differentiated gastric adenocarcinomas, 15 cases (75%) showed negative or weak staining (1+); 5 cases (25%) had moderate (2+) or strong (3+) cortactin expression. Among the 60 poorly differentiated gastric adenocarcinomas, more than three-quarters of the cases (76.7%) had moderate or strong cortactin expression; 14 cases (23.3%) had weak staining. Of 20 well-differentiated gastric adenocarcinoma cases, 14 (70%) showed negative or weak staining of fascin-1, whereas nearly one-third (30%) had moderate or strong expression. Among the 60 poorly differentiated gastric adenocarcinomas, 32 (53.3%) exhibited moderate or strong fascin-1 expression; fewer than half of the cases showed negative or weak staining. Higher intensity of cortactin and fascin-1 staining correlated directly with more-advanced cancer stages (TNM) and inversely with survival rates. Our findings suggest the possibility that pharmacological inhibitors of cortactin and fascin-1 activity may slow down tumor progression and prolong survival time in patients with gastric adenocarcinomas. (J Histochem Cytochem 55:955–962, 2007)

Key Words: fascin-1 • cortactin • gastric adenocarcinoma • survival test • immunohistochemical staining


   Introduction
Top
 Summary
 Introduction
Materials and Methods
 Results
 Discussion
 Literature Cited
 
GASTRIC CANCER was the second most common malignancy in the world in 1990 (Cunningham et al. 2006Go). Helicobacter pylori infection, diet, bile reflux, excessive cell proliferation, and DNA damage are known to be risk factors for gastric adenocarcinoma (Hemilton and Aaltonen 2000Go). Multiple other factors, such as histological features and clinical stage, have also been shown to play important roles in tumor development (Songun et al. 1999Go; Hemilton and Aaltonen 2000Go).

Recent studies indicate that enhancement of cell motility and loss of cell–cell adhesion is essential to tumor progression (Matsudaira 1994Go; Otto 1994Go; Tilney et al. 1998Go). Cortactin and fascin-1 are two important components among these actin cross-linking proteins (Hashimoto et al. 2005Go; Luo et al. 2006Go). Identification of mechanisms promoting tumor cell invasion may help direct creation of new therapies that can arrest local invasion and metastatic spread of gastric adenocarcinoma.

Cortactin is an actin-binding protein that activates the Arp2/3 complex to regulate the actin cytoskeleton (Daly 2004Go; van Rossum et al. 2006Go) and inhibit debranching of dendritic actin networks (Weaver et al. 2001Go). The gene responsible for cortactin expression is in the chromosome 11q13 region and is frequently amplified in some human cancers, such as breast and head/neck carcinomas (Schuuring 1995Go; Ormandy et al. 2003Go). Remodeling of the actin cytoskeleton has effects on cell migration, motility, and adhesion, as well as on tumor invasion and metastasis (van Rossum et al. 2006Go). In some studies, the amplification of 11q13 and overexpression of cortactin correlate with poor prognosis for patients with lymph node metastasis (Schuuring et al. 1992Go; Schuuring 1995Go; Ormandy et al. 2003Go). However, the relationship between cortactin expression and clinicopathological parameters of gastric adenocarcinoma remains vague.

Fascin, an actin-binding protein, is involved in the rearrangement of the cytoskeleton and promotes cellular motility (Roma and Prayson 2005Go). Fascin–actin interactions are regulated by the extracellular matrix, peptide factors, and other actin-binding proteins (Adams 2004aGo). In the human body, the genome encodes three subtypes of the fascin family, including fascin-1, fascin-2, and fascin-3 (Hashimoto et al. 2005Go). The level of fascin is low or undetectable in normal epithelial cells (Tong et al. 2005Go). Fascin overexpression has been reported to be associated with several different types of tumors, including breast, colon, brain, esophagus, stomach, lung, urinary bladder, and even hematological malignancies (Grothey et al. 2000Go; Fan et al. 2003Go; Pelosi et al. 2003Go; Hashimoto et al. 2004Go; Hashimoto et al. 2005Go; Roma and Prayson 2005Go; Xie et al. 2005Go).

In this study, we tested the hypothesis that higher expression of cortactin and fascin-1 in gastric adenocarcinoma patients correlates with clinicopathological parameters associated with advanced cancer stages and with decreased survival rates. The hypothesis that we set out to test is that increased cortactin and fascin-1 immunostaining intensities correlate with advanced histological grades, advanced clinical stages, and poorer prognosis for gastric adenocarcinoma patients.


   Materials and Methods
Top
 Summary
 Introduction
 Materials and Methods
Results
 Discussion
 Literature Cited
 
Paraffin-embedded tumor tissues were obtained and tissue microarray slides were constructed. The tissue microarray included samples from 100 patients with gastric adenocarcinoma, including 20 well-differentiated cases (>95% showing glandular structure), 20 moderately differentiated cases (glandular structure seen in 50–95%), and 60 poorly differentiated adenocarcinomas (glandular structure in <50%). The pathological diagnosis of these cases was reviewed by at least two experienced pathologists. The histopathological differentiation of gastric adenocarcinoma was determined according to World Health Organization criteria for tumor classification (Hemilton and Aaltonen 2000Go). These 100 gastric adenocarcinoma patients comprised 58 males and 42 females. Age distribution ranged from 33 to 89 years; the mean was 66.7. Other information, including histopathological differentiation and staging distribution, is listed in Table 1 . All experiments were approved by a human tissue committee.


View this table:
[in this window]
[in a new window]

  		Table 1

Clinicopathologic characteristics of 100 patients with gastric adenocarcinoma

 
One core tissue sample was taken from a selected area of each paraffin-embedded tumor tissue, and tissue microarray slides were constructed. Each representative core sample in the tissue microarray slide was 2 mm in diameter. The pathological diagnosis in each case was reviewed by at least two experienced pathologists. No cases had received radiation or chemotherapy before surgery.

Immunohistochemistry
Tissue microarray sections were dewaxed in xylene, rehydrated in alcohol, and immersed in 3% hydrogen peroxide for 5 min to suppress endogenous peroxidase activity. Antigen retrieval was performed by heating (at 100C) each section for 30 min in 0.01 mol/l sodium citrate buffer (pH 6.0). After three rinses [each for 5 min in phosphate-buffered saline (PBS)], sections were incubated for 1 hr at room temperature with a polyclonal goat anti-rabbit cortactin antibody (1:100; Santa Cruz Biotechnology, Santa Cruz, CA) and a monoclonal mouse anti-human fascin-1 antibody (1:100; NeoMarkers, Fremont, CA), both diluted in PBS. After three washes (each for 5 min in PBS), sections were incubated with biotin-labeled secondary immunoglobulin (1:100; DAKO, Glostrup, Denmark) for 1 hr at room temperature. After three additional washes, peroxidase activity was developed with AEC+ substrate chromogen (DAKO) at room temperature.

For assessment of cortactin and fascin-1 immunoexpression, we modified the immunoscoring of two published experiments about fascin-1 overexpression in gastric and brain tumors (Hashimoto et al. 2004Go; Roma and Prayson 2005Go). The intensities of cytoplasmic and membranous immunostaining were rated on a scale with scores shown as 0 (negative staining for tumor cells), 1+ (positive staining for 5–25% tumor cells), 2+ (positive staining for 26–50% tumor cells), and 3+ (positive staining for more than 50% tumor cells). For these biomarker analyses, tumors with <5% of cells showing cytoplasmic and membranous immunoexpression were considered to be negative for the biomarker.

Statistical Analysis
The immunostaining intensities of cortactin and fascin-1 in gastric adenocarcinomas were compared with normal esophageal squamous epithelium that had been shown to have negative staining for these biomarkers (Luo et al. 2006Go). Statistical analysis was performed using the Pearson Product Method Correlation test to analyze the relationships between the expression of these two biomarkers and clinicopathological parameters in gastric adenocarcinoma patients.

In addition, survival time was calculated from patients' date of surgery to date of death. Seventy-five gastric adenocarcinoma cases were followed up for 3 years. Cases that were included in survival analysis were divided into four groups reflecting the four possible staining scores, 0, 1, 2, or 3 to allow comparison of survival time with cortactin and fascin-1 immunostaining intensities. Statistical analysis of survival time was done using the Kaplan-Meier survival test.


   Results
Top
 Summary
 Introduction
 Materials and Methods
 Results
Discussion
 Literature Cited
 
Immunostaining of Cortactin Correlates With Histological Grades and Clinical Stages of Gastric Adenocarcinomas
Among 20 cases with well-differentiated gastric adenocarcinoma, 4 cases (20%) showed negative staining, 11 cases (55%) presented weak positive staining (1+), 2 cases (10%) revealed moderate staining, and 3 cases (15%) exhibited strong staining of cortactin. Among the 20 cases with moderately differentiated and 60 cases with poorly differentiated gastric adenocarcinomas, no case showed negative staining for cortactin, 4 (20%) and 14 (23.3%) cases presented weak staining, 7 (35%) and 27 (45%) cases revealed moderate staining, and 9 (45%) and 19 (31.7%) cases exhibited strong expression of cortactin, respectively. Using the Pearson Product Method Correlation test, overexpression of cortactin showed a positive correlation with histological grading of gastric adenocarcinomas (p<0.05; Figure 1 ; Table 2 ). Negative (0) or weak staining (1+) for cortactin was seen in 9 of 14 cases (64.3%) in T1 stage, in 6 of 14 cases (42.8%) in T2 stage, in 15 of 49 cases (30.7%) in T3 stage, and in 3 of 23 cases (13.1%) in T4 stage. In contrast, moderate (2+) or strong (3+) staining for cortactin was seen in 5 of 14 cases (35.7%) in T1 stage, 8 of 14 cases (57.2%) in T2 stage, 34 of 49 cases (69.4%) in T3 stage, and 20 of 23 cases (86%) in T4 stage. Advanced T stage correlated significantly with higher cortactin immunostaining intensity (p<0.05). Similarly, 15 of 25 cases (60%) in stage 1 had negative (0) or weak staining (1+), but more than half of the cases in stages 2, 3, and 4 showed moderate (2+) to strong (3+) staining for cortactin. Higher immunostaining intensity for cortactin also correlated significantly with advanced clinical stages (p<0.05;Figure 2 ; Table 2).


Figure 1
View larger version (111K):
[in this window]
[in a new window]

  		Figure 1

Hematoxylin and eosin staining of well-differentiated (A), moderately differentiated (D), and poorly differentiated (G) gastric adenocarcinoma; immunohistochemical analysis of cortactin in well-differentiated (B), moderately differentiated (E), and poorly differentiated (H) gastric adenocarcinoma; and immunohistochemical analysis of fascin-1 in well-differentiated (C), moderately differentiated (F), and poorly differentiated (I) gastric adenocarcinoma.

 

View this table:
[in this window]
[in a new window]

  		Table 2

The intensity of cortactin immunostaining and clinicopatholigcal parameters of gastric adenocarcinoma

 

Figure 2
View larger version (20K):
[in this window]
[in a new window]

  		Figure 2

Correlation between clinicopathological data and cortactin immunostaining intensity in gastric adenocarcinoma.

 
Immunostaining of Fascin-1 Correlates With Histological Grades and Clinical Stages of Gastric Adenocarcinomas
Among the 100 gastric adenocarcinomas, negative (0) or weak (1+) staining was seen in 14 of 20 well-differentiated cases (70%), 11 of 20 moderately differentiated cases (55%), and 28 of 60 poorly differentiated cases (46.7%). In contrast, the percentage of cases showing moderate to strong expression of fascin-1 in well-differentiated gastric adenocarcinomas was lower than the percentage in moderately or poorly differentiated tumors. Statistical analysis showed a positive correlation of fascin-1 immunostaining intensity with histological grading (p<0.05; Figure 1; Table 3 ). In addition, the percentage of cases in T1 (78.6%) and T2 (85.7%) stages of gastric adenocarcinoma showing negative or weak staining of fascin-1 were higher than the percentage of cases in T3 (44.9%) and T4 (34.8%) stages. T stages correlated significantly with higher fascin-1 immunostaining intensity (p<0.05; Figure 3 ; Table 3). Similarly, 18 of 25 cases (72%) with stage 1 and 10 of 15 cases (66.6%) with stage 2 had negative (0) or weak (1+) staining, but more than half of stage 3 (51.2%) and stage 4 (71.5%) cases showed moderate (2+) to strong (3+) staining for fascin-1. Higher immunostaining intensity for fascin-1 also correlated significantly with advanced clinical stages (p<0.05; Table 3). Similarly, the more-advanced N stage also had higher immunostaining intensity (p<0.05; Figure 3; Table 3).


View this table:
[in this window]
[in a new window]

  		Table 3

The intensity of fascin-1 immunostaining and clinicopatholigcal parameters of gastric adenocarcinoma

 

Figure 3
View larger version (21K):
[in this window]
[in a new window]

  		Figure 3

Correlation between clinicopathological data and fascin-1 immunostaining intensity in gastric adenocarcinoma.

 
Relationship Between Immunostaining for Cortactin and Fascin-1 and Survival Time
The 75 gastric adenocarcinoma cases receiving 3-year follow-up were divided into four groups based on the immunostaining intensities of cortactin and fascin-1. Using cortactin and fascin-1 immunostaining intensities as independent variables, higher intensities for these biomarkers were associated with a poorer prognosis (Figures 4 and 5 ).


Figure 4
View larger version (15K):
[in this window]
[in a new window]

  		Figure 4

Overall survival of 75 patients with gastric adenocarcinoma. Higher cortactin immunostaining intensities were associated with worse survival. Survival rates were analyzed using the Kaplan-Meier survival test (*p<0.05).

 

Figure 5
View larger version (15K):
[in this window]
[in a new window]

  		Figure 5

Overall survival of 75 patients with gastric adenocarcinoma. Higher fascin-1 immunostaining intensities were associated with worse survival, but did not reach statistical significance. Survival rates were analyzed using the Kaplan-Meier survival test (p>0.05).

 

   Discussion
Top
 Summary
 Introduction
 Materials and Methods
 Results
 Discussion
Literature Cited
 
Gastric adenocarcinoma is one of the most prevalent cancers worldwide, and clinical management leads to mostly unsatisfactory outcomes. Partial or total gastrectomy is the curative treatment, but tumor recurrence or metastasis often causes treatment to fail. Gastric adenocarcinoma spreads by direct tumor invasion, metastasis, and peritoneal dissemination (Hemilton and Aaltonen 2000Go). Some precursor lesions of gastric adenocarcinoma have been identified, such as atrophic gastritis, intestinal metaplasia, adenoma, polyp, and intraepithelial neoplasia (Hemilton and Aaltonen 2000Go). In recent studies, abnormal expression of the cell adhesion protein E-cadherin led to tumor progression of gastric adenocarcinoma (Gayther et al. 1998Go; Guilford et al. 1999Go). The prognosis for patients with gastric adenocarcinoma depends on the depth of tumor invasion and American Joint Committee on Cancer (AJCC) staging system (Hemilton and Aaltonen 2000Go).

Cortactin regulates the actin cytoskeleton through its involvement in several processes, including cell motility, adhesion, polarization, contraction, and others (Weed and Parsons 2001Go; Daly 2004Go; van Rossum et al. 2005aGo). The activation of actin-related (Arp) 2/3 protein complex and neuronal Wiscott-Aldrich Syndrome protein (N-Wasp) by cortactin nucleates actin polymerization and promotes cellular motility (Greer et al. in press). Cortactin is a p80/p85 multidomain actin filament-binding protein (Schuuring et al. 1993Go) and was first identified as an src kinase substrate in chicken fibroblasts (Wu et al. 1991Go). Human cortactin maps to chromosome 11q13 (Luo et al. 2006Go). The amplification of chromosome 11q13 has been reported in several human carcinomas as has increased expression of cortactin (van Rossum et al. 2005bGo). Overexpression of cortactin induces cell motility and migration, inhibits cell–cell adhesion, and accelerates tumor spreading (van Rossum et al. 2006Go). In addition, the effect of cortactin may be related to the expression of E-cadherin and its effects on intercellular adhesion (Kovacs et al. 2002Go; Helwani et al. 2004Go; Verma et al. 2004Go). In some in vitro studies, cortactin overexpression induced tumor invasion, and metastasis has been shown to be associated with esophageal and head/neck squamous cell carcinomas (Luo et al. 2006Go; Rothschild et al. 2006Go). However, direct evidence is still lacking to establish a relationship between cortactin overexpression and tumor progression and metastasis in gastric adenocarcinoma.

Fascin-1, a 55-kDa globular protein, aggregates F actin into parallel bundles to rearrange the cytoskeleton and promote cellular motility (Kureishy et al. 2002Go; Adams 2004aGo). It plays important roles in cellular protrusion and migration, and extracellular matrix adhesion (Adams 2004bGo). The gene encoding fascin-1 in humans is located at chromosome 7q22 (Hashimoto et al. 2005Go). Fascin-1 expression in normal gastric epithelia was shown to be undetectable (Pelosi et al. 2003Go). Overexpression of fascin-1 is associated with tumor progression and invasion in lung, gastric, esophageal, and breast carcinomas (Grothey et al. 2000Go; Hu et al. 2000Go; Fan et al. 2003Go; Jawhari et al. 2003Go; Pelosi et al. 2003Go). Our results suggest that the expression of fascin-1 may be effective in predicting tumor clinicopathological parameters of gastric adenocarcinoma in Chinese patients.

Average immunostaining intensity for cortactin and fascin has a significant positive correlation with T, N, and AJCC stages, but not with M stage. However, in our results, a greater percentage of M1 stage cases had stronger immunostaining intensity for these biomarkers than did the M0 stage. The fact that gastric adenocarcinoma cases in the M0 stage outnumbered those in M1-stage cases may have made it difficult to show statistical significance.

Until now, direct evidence has been lacking to establish a relationship between cortactin overexpression and survival rate in gastric adenocarcinoma. In our study, we successfully demonstrated that cortactin immunostaining intensity correlates with clinicopathological parameters and prognosis in gastric adenocarcinoma patients. To our knowledge, this is the first report to evaluate the association between cortactin expression and tumor progression in gastric adenocarcinoma patients. Similarly, greater immunostaining intensity of fascin-1 also correlated with higher histological grading, AJCC staging, and poorer prognosis in Chinese patients with gastric adenocarcinoma. The expression of fascin-1 in gastric adenocarcinoma in Chinese patients was similar to that in the results of a previous Japanese study (Hashimoto et al. 2004Go). Our results support the hypothesis that these two biomarkers are important prognostic factors for gastric adenocarcinoma.

In conclusion, higher cortactin and fascin immunostaining intensities in gastric adenocarcinoma tumor tissues are associated with shorter survival time and more-advanced TNM stages. Although multiple factors contribute to tumor progression, we show that cortactin and fascin-1 are satisfactory biomarkers for predicting clinical outcomes in gastric adenocarcinoma. Moreover, there is the possibility that development of pharmacological agents that inhibit cortactin and fascin-1 pathways may prolong survival time and arrest tumor progression in gastric adenocarcinoma patients.


   Acknowledgments
 
This study was supported by grants from the National Science Council (NSC95-2320-B-016-024) and Tri-Service General Hospital (TSGH-C96-14-S01 and TSGH-C96-90), Taiwan, R. O. C.


   Footnotes
 
Received for publication March 13, 2007; accepted May 8, 2007


   Literature Cited
Top
 Summary
 Introduction
 Materials and Methods
 Results
 Discussion
 Literature Cited
 

Adams JC (2004a) Roles of fascin in cell adhesion and motility. Curr Opin Cell Biol 16:590–596[CrossRef][Medline]

Adams JC (2004b) Fascin protrusions in cell interactions. Trends Cardiovasc Med 14:221–226[CrossRef][Medline]

Cunningham SC, Kamangar F, Kim MP, Hammoud S, Haque R, Iacobuzio-Donahue CA, Maitra A, et al. (2006) Claudin-4, mitogen-activated protein kinase kinase 4, and stratifin are markers of gastric adenocarcinoma precursor lesions. Cancer Epidemiol Biomarkers Prev 15:281–287[Abstract/Free Full Text]

Daly RJ (2004) Cortactin signalling and dynamic actin networks. Biochem J 382:13–25[CrossRef][Medline]

Fan G, Kotylo P, Neiman RS, Braziel RM (2003) Comparison of fascin expression in anaplastic large cell lymphoma and Hodgkin disease. Am J Clin Pathol 119:199–204[CrossRef][Medline]

Gayther SA, Gorringe KL, Ramus SJ, Huntsman D, Roviello F, Grehan N, Machado JC, et al. (1998) Identification of germ-line E-cadherin mutations in gastric cancer families of European origin. Cancer Res 58:4086–4089[Abstract/Free Full Text]

Greer RO Jr, Said S, Shroyer KR, Marileila VG, Weed SA (In Press) Overexpression of cyclin D1 and cortactin is primarily independent of gene amplification in salivary gland adenoid cystic carcinoma. Oral Oncol. Published online November 16, 2006 (DOI: 10.1016/j.oraloncology.2006.09.007)

Grothey A, Hashizume R, Sahin AA, McCrea PD (2000) Fascin, an actin-bundling protein associated with cell motility, is upregulated in hormone receptor negative breast cancer. Br J Cancer 83:870–873[CrossRef][Medline]

Guilford PJ, Hopkins JB, Grady WM, Markowitz SD, Willis J, Lynch H, Rajput A, et al. (1999) E-cadherin germline mutations define an inherited cancer syndrome dominated by diffuse gastric cancer. Hum Mutat 14:249–255[CrossRef][Medline]

Hashimoto Y, Shimada Y, Kawamura J, Yamasaki S, Imamura M (2004) The prognostic relevance of fascin expression in human gastric carcinoma. Oncology 67:262–270[CrossRef][Medline]

Hashimoto Y, Skacel M, Adams JC (2005) Roles of fascin in human carcinoma motility and signaling: prospects for a novel biomarker? Int J Biochem Cell Biol 37:1787–1804[CrossRef][Medline]

Helwani FM, Kovacs EM, Paterson AD, Verma S, Ali RG, Fanning AS, Weed SA, et al. (2004) Cortactin is necessary for E-cadherin-mediated contact formation and actin reorganization. J Cell Biol 164:899–910[Abstract/Free Full Text]

Hemilton SR, Aaltonen LA (2000) Tumors of the Digestive System in WHO Classification of Tumors. Lyon, IRAC Press, 39–52

Hu W, McCrea PD, Deavers M, Kavanagh JJ, Kudelka AP, Verschraegen CF (2000) Increased expression of fascin, motility associated protein, in cell cultures derived from ovarian cancer and in borderline and carcinomatous ovarian tumors. Clin Exp Metastasis 18:83–88[CrossRef][Medline]

Jawhari AU, Buda A, Jenkins M, Shehzad K, Sarraf C, Noda M, Farthing MJ, et al. (2003) Fascin, an actin-bundling protein, modulates colonic epithelial cell invasiveness and differentiation in vitro. Am J Pathol 162:69–80[Abstract/Free Full Text]

Kovacs EM, Goodwin M, Ali RG, Paterson AD, Yap AS (2002) Cadherin-directed actin assembly: E-cadherin physically associates with the Arp2/3 complex to direct actin assembly in nascent adhesive contacts. Curr Biol 12:379–382[CrossRef][Medline]

Kureishy N, Sapountzi V, Prag S, Anilkumar N, Adams JC (2002) Fascins, and their roles in cell structure and function. Bioessays 24:350–361[CrossRef][Medline]

Luo ML, Shen XM, Zhang Y, Wei F, Xu X, Cai Y, Zhang X, et al. (2006) Amplification and overexpression of CTTN (EMS1) contribute to the metastasis of esophageal squamous cell carcinoma by promoting cell migration and anoikis resistance. Cancer Res 66:11690–11699[Abstract/Free Full Text]

Matsudaira P (1994) Actin crosslinking proteins at the leading edge. Semin Cell Biol 5:165–174[Medline]

Ormandy CJ, Musgrove EA, Hui R, Daly RJ, Sutherland RL (2003) Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res Treat 78:323–335[CrossRef][Medline]

Otto JJ (1994) Actin-bundling proteins. Curr Opin Cell Biol 6:105–109[CrossRef][Medline]

Pelosi G, Pastorino U, Pasini F, Maissoneuve P, Fraggetta F, Iannucci A, Sonzogni A, et al. (2003) Independent prognostic value of fascin immunoreactivity in stage I nonsmall cell lung cancer. Br J Cancer 88:537–547[CrossRef][Medline]

Roma AA, Prayson RA (2005) Fascin expression in 90 patients with glioblastoma multiforme. Ann Diagn Pathol 9:307–311[CrossRef][Medline]

Rothschild BL, Shim AH, Ammer AG, Kelley LC, Irby KB, Head JA, Chen L, et al. (2006) Cortactin overexpression regulates actin-related protein 2/3 complex activity, motility, and invasion in carcinomas with chromosome 11q13 amplification. Cancer Res 66:8017–8025[Abstract/Free Full Text]

Schuuring E (1995) The involvement of the chromosome 11q13 region in human malignancies: cyclin D1 and EMS1 are two new candidate oncogenes—a review. Gene 159:83–96[CrossRef][Medline]

Schuuring E, Verhoeven E, Litvinov S, Michalides RJ (1993) The product of the EMS1 gene, amplified and overexpressed in human carcinomas, is homologous to a v-src substrate and is located in cell-substratum contact sites. Mol Cell Biol 13:2891–2898[Abstract/Free Full Text]

Schuuring E, Verhoeven E, van Tinteren H, Peterse JL, Nunnink B, Thunnissen FB, Devilee P, et al. (1992) Amplification of genes within the chromosome 11q13 region is indicative of poor prognosis in patients with operable breast cancer. Cancer Res 52:5229–5234[Abstract/Free Full Text]

Songun I, van de Velde CJ, Arends JW, Blok P, Grond AJ, Offerhaus GJ, Hermans J, et al. (1999) Classification of gastric carcinoma using the Goseki system provides prognostic information additional to TNM staging. Cancer 85:2114–2118[CrossRef][Medline]

Tilney LG, Connelly PS, Vranich KA, Shaw MK, Guild GM (1998) Why are two different cross-linkers necessary for actin bundle formation in vivo and what does each cross-link contribute? J Cell Biol 143:121–133[Abstract/Free Full Text]

Tong GX, Yee H, Chiriboga L, Hernandez O, Waisman J (2005) Fascin-1 expression in papillary and invasive urothelial carcinomas of the urinary bladder. Hum Pathol 36:741–746[CrossRef][Medline]

van Rossum AG, Gibcus J, van der Wal J, Schuuring E (2005a) Cortactin overexpression results in sustained epidermal growth factor receptor signaling by preventing ligand-induced receptor degradation in human carcinoma cells. Breast Cancer Res 7:235–237[CrossRef][Medline]

van Rossum AG, Moolenaar WH, Schuuring E (2006) Cortactin affects cell migration by regulating intercellular adhesion and cell spreading. Exp Cell Res 312:1658–1670[CrossRef][Medline]

van Rossum AG, Schuuring-Scholtes E, van Buuren-van Seggelen V, Kluin PM, Schuuring E (2005b) Comparative genome analysis of cortactin and HS1: the significance of the F-actin binding repeat domain. BMC Genomics 6:15[CrossRef][Medline]

Verma S, Shewan AM, Scott JA, Helwani FM, den Elzen NR, Miki H, Takenawa T, et al. (2004) Arp2/3 activity is necessary for efficient formation of E-cadherin adhesive contacts. J Biol Chem 279:34062–34070[Abstract/Free Full Text]

Weaver AM, Karginov AV, Kinley AW, Weed SA, Li Y, Parsons JT, Cooper JA (2001) Cortactin promotes and stabilizes Arp2/3-induced actin filament network formation. Curr Biol 11:370–374[CrossRef][Medline]

Weed SA, Parsons JT (2001) Cortactin: coupling membrane dynamics to cortical actin assembly. Oncogene 20:6418–6434[CrossRef][Medline]

Wu H, Reynolds AB, Kanner SB, Vines RR, Parsons JT (1991) Identification and characterization of a novel cytoskeleton-associated pp60src substrate. Mol Cell Biol 11:5113–5124[Abstract/Free Full Text]

Xie JJ, Xu LY, Zhang HH, Cai WJ, Mai RQ, Xie YM, Yang ZM, et al. (2005) Role of fascin in the proliferation and invasiveness of esophageal carcinoma cells. Biochem Biophys Res Commun 337:355–362[CrossRef][Medline]


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jhc.7A7235.2007v1
55/9/955    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tsai, W.-C.
Right arrow Articles by Chao, Y.-C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tsai, W.-C.
Right arrow Articles by Chao, Y.-C.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


Guidelines | Subscriptions | About | exPRESS - Current - Archive | Business Information | Contact